Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to $68.7 million.

  • Voyager Therapeutics' Non-Current Assets rose 3066.28% to $68.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $387.2 million, marking a year-over-year increase of 9428.16%. This contributed to the annual value of $116.2 million for FY2024, which is 26788.62% up from last year.
  • According to the latest figures from Q3 2025, Voyager Therapeutics' Non-Current Assets is $68.7 million, which was up 3066.28% from $94.2 million recorded in Q2 2025.
  • Voyager Therapeutics' 5-year Non-Current Assets high stood at $116.2 million for Q4 2024, and its period low was $31.6 million during Q4 2023.
  • Its 5-year average for Non-Current Assets is $57.1 million, with a median of $54.7 million in 2024.
  • In the last 5 years, Voyager Therapeutics' Non-Current Assets tumbled by 3932.39% in 2022 and then skyrocketed by 26788.62% in 2024.
  • Over the past 5 years, Voyager Therapeutics' Non-Current Assets (Quarter) stood at $57.2 million in 2021, then plummeted by 39.02% to $34.9 million in 2022, then decreased by 9.35% to $31.6 million in 2023, then surged by 267.89% to $116.2 million in 2024, then plummeted by 40.88% to $68.7 million in 2025.
  • Its last three reported values are $68.7 million in Q3 2025, $94.2 million for Q2 2025, and $108.0 million during Q1 2025.